Preclinical studies using VISTA knockout mice or anti-VISTA antibodies showed significant enhancement of antigen-specific T cell responses in vaccine models and anti-tumor activity in a variety of immunocompetent, syngeneic tumor models [12,13]. This evidence concerns the gene VSIR and neoplasm.